^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Excerpt:
Median overall survival was 21·4 months (95% CI 13·8-NE) with ACP versus 18·7 months (95% CI 13·4-NE) with BCP in EGFR-positive patients (HR 0·93 [95% CI 0·51-1·68]).
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1016/S2213-2600(19)30084-0
Trial ID:
